Loading...

GSK

GSK

GSK PLC

(GSK)

2025 6-K

Show Summary

Summary

Share Buyback Report

2 Sep '25

Voting Rights Update

2 Sep '25

Share Buyback Update

2 Sep '25

Share Buyback Update

29 Aug '25

Share Buyback

28 Aug '25

Share Buyback Update

27 Aug '25

Share Buyback Announcement

26 Aug '25

Share Buyback Announcement

22 Aug '25

Shareholding Update

21 Aug '25

Share Buyback Report

21 Aug '25

Share Buyback Update

20 Aug '25

Equity Acquisition

19 Aug '25

Share Buyback Update

19 Aug '25

Share Buyback Activity

18 Aug '25

Share Buyback Update

15 Aug '25

Share Buyback Announcement

14 Aug '25

Share Buyback Update

13 Aug '25

Executive Share Acquisition

12 Aug '25

Share Buyback Announcement

12 Aug '25

FDA Review Acceptance

11 Aug '25

Share Buyback Update

11 Aug '25

Patent Settlement

8 Aug '25

Share Buyback Announcement

8 Aug '25

Share Buyback Announcement

7 Aug '25

Share Buyback Announcement

6 Aug '25

Share Buyback Update

5 Aug '25

Share Buyback Announcement

4 Aug '25

Voting Rights Update

1 Aug '25

Share Buyback Process

1 Aug '25

Share Buyback Update

31 Jul '25

Strong 2Q Performance

30 Jul '25

Share Buyback Update

30 Jul '25

Share Buyback Announcement

29 Jul '25

New Collaboration

28 Jul '25

Share Buyback Update

28 Jul '25

Share Buyback Announcement

25 Jul '25

Blenrep Approval

24 Jul '25

Share Buyback Details

24 Jul '25

FDA Review Extended

23 Jul '25

Share Buyback Announcement

23 Jul '25

Share Buyback Update

22 Jul '25

Share Buyback Announcement

21 Jul '25

Share Acquisition Notification

18 Jul '25

FDA Advisory Committee Outcome

18 Jul '25

Share Buyback Announcement

18 Jul '25

Shingrix Approval

17 Jul '25

Share Buyback Process

17 Jul '25

Share Buyback Announcement

16 Jul '25

Share Acquisitions

15 Jul '25

Share Buyback Update

15 Jul '25

Share Acquisitions

14 Jul '25

FDA Review Submission

14 Jul '25

Share Buyback Update

14 Jul '25

Share Buyback Details

11 Jul '25

Share Buyback Announcement

10 Jul '25

Share Buyback Announcement

9 Jul '25

Share Buyback

8 Jul '25

GSK Acquisition Complete

7 Jul '25

Share Buyback Program

7 Jul '25

Share Buyback

7 Jul '25

Share Buyback Update

3 Jul '25

Share Buyback Announcement

2 Jul '25

Voting Rights Update

1 Jul '25

Share Buyback Update

1 Jul '25

Share Buyback Update

30 Jun '25

Share Buyback Activity

27 Jun '25

Share Buyback Update

26 Jun '25

Share Buyback Update

25 Jun '25

Share Transactions

24 Jun '25

Director Appointment

24 Jun '25

Share Buyback Acquisition

24 Jun '25

Share Purchases Revealed

23 Jun '25

Drug Review Accepted

23 Jun '25

Share Buyback Update

23 Jun '25

RSV Vaccine Update

20 Jun '25

Share Buyback Program

20 Jun '25

Share Buyback Update

20 Jun '25

Share Buyback Announcement

18 Jun '25

Share Buyback Update

17 Jun '25

Share Buyback Announcement

16 Jun '25

Share Sale Notification

13 Jun '25

Share Buyback Program

13 Jun '25

RSV Vaccine Update

13 Jun '25

Director Shareholding

12 Jun '25

Share Buyback Update

12 Jun '25

Share Sale Notification

11 Jun '25

Share Buyback Update

11 Jun '25

Share Buyback Program

10 Jun '25

Share Buyback Announcement

9 Jun '25

Share Buyback Announcement

6 Jun '25

Share Buyback Update

5 Jun '25

Share Buyback Announcement

4 Jun '25

Share Buyback Announcement

4 Jun '25

Share Buyback Announcement

3 Jun '25

Share Sale Notification

2 Jun '25

Voting Rights Update

2 Jun '25

FDA Review Acceptance

2 Jun '25

Share Buyback Report

2 Jun '25

Share Buyback Report

30 May '25

Share Buyback Announced

29 May '25

Trial Stopped Early

28 May '25

Share Buyback Announcement

28 May '25

Share Buyback Announcement

27 May '25

Positive CHMP Opinion

23 May '25

FDA Approval News

23 May '25

Share Buyback Announced

23 May '25

Share Buyback Update

22 May '25

Share Buyback Activity

21 May '25

Shareholding Update

20 May '25

Share Buyback Announcement

20 May '25

Blenrep Approval

19 May '25

Share Buyback Announcement

19 May '25

Share Buyback Announcement

16 May '25

Share Buyback Announcement

15 May '25

GSK Acquisition Announcement

14 May '25

Share Buyback Announcement

14 May '25

Share Acquisitions

13 May '25

Belrestotug Development Ended

13 May '25

Share Buyback Update

13 May '25

Block Listing Update

12 May '25

Share Buyback Update

12 May '25

Share Buyback Update

9 May '25

CEO Share Award

8 May '25

Share Vesting Update

8 May '25

Linerixibat Trial Results

8 May '25

Share Buyback Update

8 May '25

AGM Results Report

7 May '25

Share Buyback Announcement

7 May '25

Share Buyback Announcement

6 May '25

Share Buyback Announcement

2 May '25

Director Shareholding

1 May '25

Voting Rights Update

1 May '25

Positive Trial Results

1 May '25

Share Buyback Announcement

1 May '25

Share Buyback Announcement

30 Apr '25

Q1 2025 Results

30 Apr '25

Share Buyback Announcement

29 Apr '25

Share Buyback Update

28 Apr '25

Share Buyback Completed

25 Apr '25

Share Buyback Update

24 Apr '25

Share Buyback Activity

23 Apr '25

Share Buyback Announcement

22 Apr '25

Blenrep Approval

17 Apr '25

Dividend Reinvestment

17 Apr '25

RSV Vaccine Recommendation

17 Apr '25

Vaccine Recommendation

17 Apr '25

Share Buyback Update

17 Apr '25

Share Buyback Update

16 Apr '25

Share Acquisitions

15 Apr '25

Share Buyback Update

15 Apr '25

Director Share Acquisitions

14 Apr '25

Share Buyback Announcement

14 Apr '25

Director Share Acquisitions

11 Apr '25

Share Buyback Announcement

11 Apr '25

Share Buyback Announcement

10 Apr '25

Share Purchase Announcement

9 Apr '25

Share Buyback Announcement

8 Apr '25

Share Buyback Announcement

7 Apr '25

Share Buyback Announcement

4 Apr '25

Share Buyback Announcement

3 Apr '25

Share Buyback Announcement

2 Apr '25

Voting Rights Update

1 Apr '25

Share Repurchase Announcement

1 Apr '25

Share Buyback Announcement

31 Mar '25

Director Shareholding Changes

28 Mar '25

Share Buyback Announcement

28 Mar '25

Share Buyback Announcement

27 Mar '25

Share Buyback Announcement

26 Mar '25

FDA Approval Announcement

25 Mar '25

Share Buyback Announcement

25 Mar '25

AGM Notice Issued

24 Mar '25

Nucala Review Acceptance

24 Mar '25

Share Buyback Details

24 Mar '25

Director Shareholding

21 Mar '25

Share Buyback Update

21 Mar '25

Share Buyback Announcement

20 Mar '25

Share Buyback Program

19 Mar '25

Share Buyback Announcement

18 Mar '25

Share Buyback Announcement

17 Mar '25

Share Transactions

14 Mar '25

Buyback Announcement

14 Mar '25

Filing Notification

13 Mar '25

Share Buyback Announcement

13 Mar '25

Share Buyback Update

12 Mar '25

Share Buyback

11 Mar '25

Share Buyback Announcement

10 Mar '25

Share Buyback Update

7 Mar '25

Share Buyback Update

6 Mar '25

Share Buyback Report

5 Mar '25

Share Buyback Announcement

4 Mar '25

Annual Report Filing

3 Mar '25

Voting Rights Update

3 Mar '25

FDA Review Accepted

3 Mar '25

Clinical Trial Results

3 Mar '25

Share Buybacks Announcement

3 Mar '25

Share Buyback Announcement

28 Feb '25

Share Buyback Announcement

27 Feb '25

Annual Report Released

27 Feb '25

Director Transactions

26 Feb '25

Share Buyback Announcement

26 Feb '25

Share Buyback Plan

25 Feb '25

Acquisition Completed

24 Feb '25

Share Buyback Programme

24 Feb '25

Board Change Announced

21 Feb '25

Share Awards Granted

21 Feb '25

Bonus Awards Granted

21 Feb '25

Shareholding Update

21 Feb '25

Share Vesting Report

21 Feb '25

Share Vesting Notification

21 Feb '25

Executive Share Transactions

21 Feb '25

Nucala Drug Update

20 Feb '25

Vaccine Approval

18 Feb '25

Share Transactions

13 Feb '25

Share Vesting Report

11 Feb '25

Strong 2024 Results

5 Feb '25

Voting Rights Update

3 Feb '25

New Drug Review

28 Jan '25

EMA Review Accepted

28 Jan '25

Shingrix Review Accepted

27 Jan '25

Jemperli Approval Expansion

21 Jan '25

Share Acquisition Report

16 Jan '25

Shareholding Increase

15 Jan '25

Share Acquisitions

14 Jan '25

Share Acquisition Details

13 Jan '25

GSK Acquisition News

13 Jan '25

Shingrix FDA Review

10 Jan '25

FDA Breakthrough Designation

7 Jan '25

Nucala Approved

3 Jan '25

Voting Rights Update

2 Jan '25

Director Share Purchases

23 Dec '24

Block Listing Application

20 Dec '24

Trial Results Announced

20 Dec '24

FDA Designation Granted

16 Dec '24

EMA Designation Granted

16 Dec '24

Positive Approval Opinion

16 Dec '24

Director Shareholding Update

12 Dec '24

Blenrep Success

9 Dec '24

Regulatory Acceptance

9 Dec '24

FDA Submission Accepted

9 Dec '24

Vaccine Collaboration Extended

5 Dec '24

Transaction Notification

2 Dec '24

Voting Rights Update

2 Dec '24

Vaccine Approval

27 Nov '24

FDA Review Accepted

25 Nov '24

RSV Vaccine Approval

22 Nov '24

Share Acquisition Report

19 Nov '24

Linerixibat Success

19 Nov '24

Survival Results Announced

14 Nov '24

Block Listing Review

13 Nov '24

Director Share Transactions

12 Nov '24

Dividend Dates Announced

12 Nov '24

Voting Rights Update

1 Nov '24

Shareholding Update

30 Oct '24

Q3 2024 Results

30 Oct '24

RSV Vaccine Update

24 Oct '24

Director Shareholdings

17 Oct '24

Share Acquisitions

16 Oct '24

FDA Approval News

16 Oct '24

Director Shareholding Update

15 Oct '24

ANCHOR Trials Results

15 Oct '24

Share Acquisitions

11 Oct '24

Share Acquisition

10 Oct '24

Zantac Litigation Settlements

9 Oct '24

Positive Vaccine Data

8 Oct '24

Voting Rights Update

1 Oct '24

Director Share Purchases

24 Sep '24

Positive Vaccine Opinion

24 Sep '24

Zantac Settlements

18 Sep '24

Regulatory Review Accepted

17 Sep '24

Blenrep Therapy Designation

13 Sep '24

Director Shareholding

12 Sep '24

Positive Vaccine Results

12 Sep '24

Zantac Settlement

11 Sep '24

Office Relocation

11 Sep '24

HSV Vaccine Update

11 Sep '24

Asthma Treatment Breakthrough

9 Sep '24

Share Award Notification

6 Sep '24

Nucala Trial Success

6 Sep '24

Total Voting Rights

3 Sep '24

EMA Approval Announcement

29 Aug '24

Nucala Approved

28 Aug '24

SENKU Designation Granted

28 Aug '24

Zantac Litigation Update

28 Aug '24

Director Shareholding

21 Aug '24

Director Shareholding

20 Aug '24

FDA Designation Granted

20 Aug '24

Court Ruling Favor

16 Aug '24

Share Acquisition Report

12 Aug '24

Litigation Verdict

6 Aug '24

Jemperli Approval Expanded

2 Aug '24

Voting Rights Update

1 Aug '24

Strong Q2 Performance

31 Jul '24

Zantac Litigation Update

29 Jul '24

Positive Vaccine Opinion

29 Jul '24

EMA Review Accepted

19 Jul '24

Director Share Acquisitions

18 Jul '24

Director Shareholdings

16 Jul '24

Share Acquisitions

15 Jul '24

Management Stock Purchase

12 Jul '24

Collaboration Restructured

3 Jul '24

Voting Rights Update

1 Jul '24

Zantac Legal Settlement

28 Jun '24

EMA Approval Update

24 Jun '24

New Drug Approval

24 Jun '24

Director Shareholding

21 Jun '24

Director Shareholding

12 Jun '24

Zantac Litigation Appeal

11 Jun '24

Zantac Litigation Update

10 Jun '24

FDA Vaccine Approval

10 Jun '24

Voting Rights Report

3 Jun '24

Jemperli Trial Success

3 Jun '24

Positive Trial Results

3 Jun '24

Zantac Litigation Update

3 Jun '24

Zantac Litigation Update

24 May '24

Positive Trial Results

21 May '24

Shareholding Transactions

20 May '24

Share Sale Announcement

17 May '24

Share Sale Completion

17 May '24

Share Acquisitions

14 May '24

Block Listing Review

13 May '24

AGM Results Summary

8 May '24

Board Changes

8 May '24

Share Sale Report

3 May '24

Strong Q1 Performance

1 May '24

Voting Rights Update

1 May '24

FDA Acceptance News

24 Apr '24

Director Shareholding

19 Apr '24

Shareholding Increase

17 Apr '24

Shingrix Efficacy Update

17 Apr '24

Positive Trial Results

17 Apr '24

Shareholding Amendment

16 Apr '24

Vaccine Review Update

16 Apr '24

Share Acquisitions

15 Apr '24

Voting Rights Correction

4 Apr '24

Voting Rights Update

2 Apr '24

Director Shareholding

26 Mar '24

AGM Notice Issued

25 Mar '24

Share Transfer Report

22 Mar '24

Director Shareholding

22 Mar '24

Phase III Results

18 Mar '24

Share Sales Notification

13 Mar '24

Board Change

8 Mar '24

Positive Trial Results

7 Mar '24

HIV Treatment Update

6 Mar '24

Annual Report Filed

5 Mar '24

Long-Acting HIV Treatment

5 Mar '24

Voting Rights Update

1 Mar '24

Annual Report Released

1 Mar '24

Board Appointment

29 Feb '24

Zantac Litigation Settlement

29 Feb '24

Director Transactions

26 Feb '24

Positive Trial Results

26 Feb '24

Share Transaction Report

22 Feb '24

HIV Treatment Update

21 Feb '24

Share Vesting Update

20 Feb '24

Management Shareholding

15 Feb '24

Acquisition Completed

15 Feb '24

Share Vesting Report

13 Feb '24

Share Awards Vesting

13 Feb '24

Director Shareholding

13 Feb '24

Director Shareholding

12 Feb '24

Share Awards Granted

12 Feb '24

Bonus Share Awards

12 Feb '24

FDA Fast Track Approval

12 Feb '24

Vaccine Filing Accepted

6 Feb '24

Shingrix Approval Update

6 Feb '24

Positive Trial Results

6 Feb '24

Director Shareholding

1 Feb '24

Voting Rights Update

1 Feb '24

Zantac Settlement

1 Feb '24

Strong 2023 Performance

31 Jan '24

EMA Vaccine Filing

29 Jan '24

EU Approval Granted

29 Jan '24

Share Acquisitions

19 Jan '24

Dividend Reinvestment

17 Jan '24

Haleon Share Sale

17 Jan '24

Share Sale Completion

17 Jan '24

Share Acquisitions

16 Jan '24

Nucala Approval China

10 Jan '24

GSK Acquisition

9 Jan '24

Voting Rights Update

2 Jan '24

External Links:

SEC

GSK plc announces that its COPD treatment Nucala (mepolizumab) was accepted for review in China on February 20, 2025, targeting a significant population of around 100 million patients with the disease.

AI Assistant

GSK PLC

2025

6 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.